/
NYXH
$1.65-$0.02 (-1.20%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$166.9M
100M shares
52-week range
$1.26 – $8.59
5% from low
Exchange
NASDAQ
CS
Borrow rate
23.56%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-28.46
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $69.0K | $852.0K | $3.1M | $4.3M | $4.5M | $10.0M |
| Cost of revenue | $2.5M | $486.0K | $30.0K | $303.0K | $1.1M | $1.7M | $1.6M | $3.7M |
| Gross profit | −$2.5M | −$486.0K | $39.0K | $549.0K | $1.9M | $2.7M | $3.0M | $6.3M |
| Gross margin | — | — | 56.5% | 64.4% | 62.7% | 61.9% | 65.7% | 63.1% |
| R&D | $1.7M | $1.6M | $2.9M | $6.0M | $15.9M | $27.7M | $34.3M | $42.8M |
| Operating income | −$8.4M | −$8.5M | −$11.2M | −$26.2M | −$32.5M | −$45.1M | −$58.8M | −$82.9M |
| EBITDA | −$8.8M | −$8.2M | −$10.6M | −$22.6M | −$27.9M | −$42.1M | −$53.8M | −$82.9M |
| Net income | −$9.1M | −$9.5M | −$12.2M | −$27.6M | −$31.2M | −$43.2M | −$59.2M | −$90.1M |
| Net margin | — | — | -17746.4% | -3241.7% | -1012.5% | -993.8% | -1310.2% | -899.1% |
| EPS (diluted) | -0.43 | -0.34 | -0.68 | -1.16 | -1.21 | -1.55 | -1.81 | -2.37 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $43M | $-1.34 | $-1.63–$-0.89 | 4 |
| 2027 | $84M | $-0.96 | $-1.33–$-0.49 | 3 |
| 2028 | $136M | $-0.40 | $-0.55–$-0.25 | 2 |
| 2029 | $204M | $-0.07 | $-0.08–$-0.06 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Nyxoah SA Ordinary Shares
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
www.nyxoah.com- Employees
- 154
- IPO / List date
- Mar 5, 2021
Held by traders on TradeandTell
No one on the platform currently holds NYXH.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in NYXH as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NYXH yet.
